A Nation Unprepared: Incomplete Implementation of the National Blueprint for Biodefense

OBJECTIVE
Provide the Bipartisan Commission on Biodefense with a better understanding of federal efforts to enhance national biodefense since the 2015 release of the National Blueprint for Biodefense.

SCHEDULE

Opening Remarks

Panel One: Leadership
Former Homeland Security Advisor will discuss leadership of the federal biodefense enterprise to enhance the country’s ability to respond to the next biological threat. Addresses Recommendations 1 and 2 from the National Blueprint for Biodefense.

The Honorable Tom Bossert
President, Trinity Cyber, Inc.; Former Deputy Assistant to President Donald J. Trump for Homeland Security and Counterterrorism, The White House

Panel Two: Congressional Perspective
Sitting Member of Congress will discuss the role of the Legislative Branch in addressing biological threats. Addresses Recommendation 5 from the National Blueprint for Biodefense.

Senator Lamar Alexander (R-TN)
Chairman, Committee on Health, Education, Labor and Pensions, U.S. Senate

Panel Three: Strategies
Current and former federal officials will discuss strategic documents addressing national biodefense policy, the extent to which related policies were implemented before and during the response to COVID-19, and how to plan for future biological threats. Addresses Recommendation 3 from the National Blueprint for Biodefense.

Robert J. Roller
Chief, National Planning Branch, Planning and Exercise Division, Response Directorate, Office of Response and Recovery, Federal Emergency Management Agency
Hillary Carter, PhD
Senior Advisor, Office of Countering Weapons of Mass Destruction, Department of Homeland Security; former Director for Countering Biological Threats, National Security Council, The White House

Rajeev Venkayya, MD
President, Global Vaccine Business Unit, Takeda Pharmaceutical Company Ltd.; former Special Assistant to President George W. Bush for Biodefense, Homeland Security Council, The White House

Panel Four: Hospital Preparedness
Local and federal representatives discuss challenges in preparing healthcare institutions for large-scale biological events, and proposals for strengthening the Nation’s hospitals for future biological threats. Addresses Recommendations 19, 20 and 21 from the National Blueprint for Biodefense.

Jack Herrmann, MSEd
Acting Director, Division of National Healthcare Preparedness Programs, Office of the Assistant Secretary for Preparedness and Response, Department of Health and Human Services; former Senior Advisor and Chief, Public Health Programs, National Association of County and City Health Officials

Erica S. Shenoy, MD, PhD
Medical Director, Regional Emerging Special Pathogens Treatment Center, and Associate Chief, Infection Control Unit, Massachusetts General Hospital; Assistant Professor, Harvard Medical School

Panel Five: Supply Chain for Biodefense
A federal official and a state public health official will discuss the successes and challenges of the national medical supply chain in addressing COVID-19. Addresses Recommendations 22 and 23 from the National Blueprint for Biodefense.

David Starr
Assistant Commissioner, Emergency Field Operations, New York City Department of Health and Mental Hygiene

Mike Casey, PhD
Director, Technological Hazards Division, and Chair, Federal Radiological Preparedness Coordinating Committee, Federal Emergency Management Agency

Closing Remarks

Adjourn